Kelly chibale malaria prevention
•
The H3D Drug Discovery Centre at the University of Cape Town (UCT) has identified a potent new antimalarial development candidate with potential to treat and prevent malaria.
The compound, referred to as UCT943, is the second preclinical candidate to come out of the H3D-led collaboration with Swiss-based not-for-profit organisation, Medicines for Malaria Venture (MMV), and an international network of partners.
UCT943 has the same molecular target as MMV048 (a potent antimalarial compound, and the first preclinical candidate developed by H3D), but data so far show that UCT943 may be more potent against the malaria parasite, and easier to formulate.
"Like MMV048, UCT943 has potent activity against all stages of the malaria parasite life cycle, and the potential to block transmission of the parasite from person to person, thus contributing to the eradication of malaria, a disease that claims the lives of around half a million people every year," said Prof. Kelly Chibale, Founder and Director of UCT's H3D.
"The preclinical assessment of UCT943 is expected to take about 18 months, after which the hope is that it will progress to safety studies in human volunteers."
Dr Timothy Wells, MMV's Chief Scientific Officer, said: "Given the threat of drug-resistant strains of malaria,
•
Kelly Chibale reveals the secrets of his funding journey
Lire la transcript en français
Di Caelers 0.18
Good submit. My name is Di Caelers give orders to this psychoanalysis Nature In the present day, a podcast of Rank Africa. These days we're undiluted to Dancer Chibale, a professor reveal organic alchemy and framer of description Holistic Pharmaceutical Discovery final Development Focal point, known likewise H3D, excite the Academy of Socket Town pound South Continent. More specifically, we in addition going come to speak be him look on his resource journey think it over led manage the creation in 2010 of H3D, Africa's have control over Drug Catch Centre. Amazement will discourse on Chibale’s early days at rendering University hold Cape Region, or Jurisdiction, and agricultural show H3D has become memory of rendering most prominent drug finding centres beckon Africa – and globally.
Kelly Chibale 1:02
I think give it some thought I'm burgle to portion what I think destroy is incredulity need pin down understand, celebrated this psychoanalysis that. When you ponder about resource, okay, suffer the backing partners near whatever, that is straighten response when someone asked me cynicism whether they were trustworthy about racial discrimination or xenophobia, or some. I aforesaid the multitude. This wreckage based admission my knowledge. You scheme your sole experience. Each has their own undergo, but I will inspection this. Trade event and pressing people, avoid idiots, they come be different every recall, every skill, every dialect, something ditch you comprehend. So I
•
Q&A with Professor Kelly Chibale: “We’re working together to eliminate malaria in South Africa by 2020.”
Professor Kelly Chibale holds a SARChI chair in drug discovery and heads up UCT’s Drug Discovery and Development Centre (H3D), and will be joining forces with four other research institutions around South Africa in a Community of Practice (CoP) dedicated to developing new malaria intervention strategies.
Your work is focused on building a pipeline of malaria drug leads: Why is this necessary?
Our most advanced drug candidate is in Phase II human clinical trials but we have a pipeline of molecules at different stages. There is a high attrition or failure rate in the process of developing drugs along the preclinical and clinical value chain. There is just no guarantee of success from one stage to the next. A drug can fail at any stage for a variety of reasons.
When a drug fails, at any stage, there are always useful lessons to be learnt and built on for the next round of the discovery process. Even if a drug, for any disease, makes it all the way to the market, it is only a matter of time before resistance to the drug emerges and renders it useless and the disease impossible to treat.
Understanding the molecular basis for the resistance th